Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 2 Sets of GLs for Development of Vaccines Issued
June 28, 2010
- Meiji Seika Begins PIIa Study for Fibromyalgia with Mirtazapine
June 28, 2010
- Asahi Kasei Pharma Licenses Zoledronic Acid from Novartis
June 28, 2010
- Continued Treatment with Strattera Now Permitted after 18th Anniversary
June 28, 2010
- SymBio Licenses Lupuzor from Cephalon
June 28, 2010
- Takeda Terminates Collaboration with CanBas for CBP501
June 28, 2010
- LTT Bio-Pharma's IPF Drug Midismase Obtains Orphan Status
June 28, 2010
- JPMA Releases List of Unapproved Drugs/Indications without Development Sponsor
June 28, 2010
- GSK, Yoshitomi to Terminate Copromotion of Paxil in July
June 28, 2010
- Additional Indication Approved for Actemra in Europe: Roche
June 28, 2010
- NBI, Astellas Disagree With Meta-Analysis on Safety of Telmisartan
June 28, 2010
- Eisai Licenses Netupitant + Palonosetron Combinations from Helsinn in US
June 21, 2010
- Pfizer Oncology to Accelerate Multinational Trials to Eliminate “Drug Lag” VP S. Lowenthal
June 21, 2010
- Risk of Stroke Reduced by Intensified Intervention in Japanese Diabetes Patients
June 21, 2010
- Ranbaxy Launches Prasugrel in India
June 21, 2010
- Roche Aims to Apply for 5 Anticancer Agents by 2013: VP Hal Barron
June 21, 2010
- Radiotherapy May Be Omitted in Elderly Breast Cancer Patients
June 21, 2010
- High % of Prescriptions Still Prohibit Generic Substitution: Nihon Chouzai
June 21, 2010
- Merck Serono to Accelerate Development of Personalized Cancer Treatments: EVP W. Wein
June 21, 2010
- ROCA Screening Useful for Early Detection of Ovarian Cancer
June 21, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…